Chennai Meenakshi Multispeciality Hospital Limited reported a net profit of ₹0.28 lakh for the quarter ended June 30, 2026, reversing a net loss of ₹74.11 lakh recorded in the corresponding period of FY26. The turnaround was driven by a reduction in operating losses, with total income at ₹870.46 lakh against total expenses of ₹871.98 lakh. This marks a significant improvement from Q1FY26, where the company incurred a pre-tax loss of ₹75.59 lakh. The Board of Directors approved the unaudited financial results on August 11, 2026, alongside key leadership appointments aimed at strengthening operational and governance structures.

The filing was made under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The financial results were prepared in accordance with Indian Accounting Standard (Ind AS) as prescribed under Section 133 of the Companies Act, 2013. Elias George & Co., the statutory auditors, conducted a limited review of the interim financial information pursuant to Regulation 33 of the SEBI LODR Regulations, 2015, and issued a clean review report.

Financial Performance

Revenue from operations declined marginally to ₹859.02 lakh in Q1FY27 from ₹864.90 lakh in Q1FY26. Other income also decreased to ₹11.44 lakh from ₹26.98 lakh in the prior year quarter. Total income for the period was ₹870.46 lakh, compared to ₹891.88 lakh in Q1FY26.

Total expenses were contained at ₹871.98 lakh, down significantly from ₹967.47 lakh in Q1FY26. This reduction was primarily due to lower employee benefit expenses (₹187.89 lakh vs ₹241.61 lakh) and other expenses (₹478.16 lakh vs ₹505.14 lakh). Purchase of stock-in-trade remained stable at ₹159.83 lakh. Finance costs were ₹22.17 lakh, nearly unchanged from ₹22.22 lakh in the previous year.

Leadership Appointments

The Board appointed Dr Thanigai Vendan Moorrthy as Chief Executive Officer (in Non-Director Capacity) and Key Managerial Personnel for a term of five years, effective August 11, 2026. Dr Moorrthy is a Senior Anesthesiologist with over 15 years of clinical expertise and healthcare executive experience.

Additionally, the Board appointed three new Additional Directors in the capacity of Non-Executive Independent Directors, subject to shareholder approval at the ensuing Annual General Meeting:

• A F Simeon Telfer (DIN: 11879121), an entrepreneur with experience in business development and corporate governance.
• R V Ramanuja Bharathi (DIN: 08553270), an advocate specializing in legal strategy and corporate law.
• Sindu Chawla (DIN: 11879201), a software engineering leader with over 15 years of experience in network architecture.

Committee Reconstitution

Consequent to these appointments, the Board reconstituted its Audit Committee and Stakeholders Relationship Committee effective August 11, 2026.

Audit Committee:

• Chairman: M. Karunakaran (Independent Non-Executive Director)
• Members: A F Simeon Telfer (Independent Non-Executive Director), Jayanthi Radhakrishnan (Executive Director)

Stakeholders Relationship Committee:

• Chairman: Sindu Chawla (Independent Non-Executive Director)
• Members: R V Ramanuja Bharathi (Independent Non-Executive Director), Edward Prabhakar (Non-Executive Director)

What the Numbers Show

The shift from a significant loss to a marginal profit indicates improved cost containment rather than revenue growth. While revenue dipped slightly, the substantial reduction in total expenses—particularly in employee benefits and other operational costs—allowed the company to narrow its deficit to near break-even levels. The deferred tax credit of ₹1.80 lakh contributed to the final profit figure, offsetting the pre-tax loss of ₹1.52 lakh.

Chennai Meenakshi Multispeciality Hospital Limited has appointed M. Karunakaran as an Additional Non-Executive Independent Director for a term of five consecutive years, effective August 7, 2026. The appointment was approved by the Board of Directors during a meeting held via video conference on August 7, 2026, from 12:30 PM to 1:45 PM IST. This decision strengthens the company’s governance framework by adding an experienced professional to the boardroom, subject to shareholder approval at the ensuing Annual General Meeting.

The Board also reconstituted three key committees consequent to Mr. Karunakaran’s appointment: the Audit Committee, the Nomination and Remuneration Committee, and the Stakeholders Relationship Committee. These changes ensure compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and enhance oversight mechanisms within the organization.

Appointment Details and Profile

M. Karunakaran, holding Director Identification Number (DIN) 11874200, brings extensive experience in banking, financial management, and corporate governance. He is a retired Chief Manager of Indian Overseas Bank and is currently a practicing Advocate enrolled with the Madras Bar Association. His background includes expertise in risk assessment, credit administration, and regulatory compliance.

The company affirmed that Mr. Karunakaran is not related to any existing Director or Key Managerial Personnel (KMP) and is not debarred from holding office by any order passed by SEBI or other authorities. The appointment aligns with Section 173(3) of the Companies Act, 2013, which allows for short-notice convening of board meetings with requisite consent from independent directors.

Committee Reconstitution

Following the appointment, the Board reshuffled its committees to incorporate Mr. Karunakaran into key oversight roles:

• Audit Committee: Mr. M. Karunakaran serves as Chairman, alongside members Mrs. Shama Dhilip (Independent Director) and Mrs. Jayanthi Radhakrishnan (Executive Director).
• Nomination and Remuneration Committee: Mrs. Shama Dhilip chairs this committee, with Mr. M. Karunakaran and Mr. Akash Prabhakar (Non-Executive Director) as members.
• Stakeholders Relationship Committee: Mr. M. Karunakaran chairs this committee, supported by Mrs. Shama Dhilip and Mr. Edward Prabhakar (Non-Executive Director).

These reconstituted structures aim to improve stakeholder engagement and ensure robust financial and operational oversight. The disclosures were made in compliance with Regulation 30 of the SEBI LODR Regulations, 2015, and relevant SEBI Master Circulars.

Governance Implications

The addition of an independent director with a strong banking and legal background enhances Chennai Meenakshi Multispeciality Hospital Limited’s ability to manage risks and maintain ethical standards. Independent directors play a critical role in protecting minority shareholder interests and providing objective guidance on strategic matters. This move underscores the company’s commitment to transparent and effective corporate governance.